Search results for "Carbohydrate antigen"

showing 10 items of 14 documents

Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design.

2014

Abstract Introduction and objectives Morbidity and mortality after admission for acute heart failure remain prohibitively high. In that setting, plasma levels of antigen carbohydrate 125 have shown to correlate with the severity of fluid overload and the risk of mortality and readmission. Preliminary data suggests a potential role of antigen carbohydrate 125 to guide therapy. The objective of this study is to evaluate the prognostic effect of an antigen carbohydrate 125-guided management strategy vs standard therapy in patients recently discharged for acute heart failure. Methods This is a multicenter, randomized, single-blind, efficacy trial study of patients recently discharged from acute…

AdultMalemedicine.medical_specialtyRandomizationTime FactorsRisk AssessmentAntigenCause of DeathRisk of mortalityMedicineHumansIn patientSingle-Blind MethodProspective StudiesIntensive care medicineAgedHeart Failurebusiness.industryStandard treatmentDisease ManagementCardiovascular AgentsGeneral MedicineMiddle Agedmedicine.diseasePrognosisPatient DischargeClinical trialSurvival RateSpainHeart failureCA-125 AntigenAcute DiseaseFemalebusinessCarbohydrate antigenBiomarkersFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Serum interleukin-6 levels are elevated in women with minimal-mild endometriosis.

2006

BACKGROUND: There is a need for a reliable marker of endometriosis, especially in early stages of peritoneal disease during which imaging is not effective. The use of serum interleukin (IL)-6 as a marker is controversial. To readdress the matter, patients undergoing laparoscopy were prospectively evaluated for serum IL-6 levels. MATERIALS AND METHODS: A total of 119 women 31 years old who underwent laparoscopy were divided into groups: control patients (n = 38) with no pathologic findings; endometriosis sufferers (n = 47) with minimal-mild (MM, n = 11) or moderate-severe (MS, n = 36) endometriosis; uterine myomas (n = 13) and benign ovarian pathologies (n = 21). Blood was drawn on cycles da…

Adultmedicine.medical_specialtyEndometriosisEndometriosisGastroenterologySensitivity and SpecificityInternal medicinemedicineHumansProspective StudiesInterleukin 6LaparoscopyProspective cohort studyGynecologybiologymedicine.diagnostic_testbusiness.industryInterleukin-6RehabilitationCase-control studyObstetrics and GynecologyInterleukinmedicine.diseaseReproductive MedicineROC CurveCA-125 AntigenCase-Control Studiesbiology.proteinFemaleLaparoscopyPeritoneal diseasesbusinessCarbohydrate antigenHuman reproduction (Oxford, England)
researchProduct

The emerging role of carbohydrate antigen 125 in heart failure.

2020

Heart Failurebusiness.industryBiochemistry (medical)Clinical Biochemistrymedicine.diseaseRisk AssessmentHeart failureCA-125 AntigenDrug DiscoveryImmunologyRisk stratificationmedicineBiomarker (medicine)HumansbusinessCarbohydrate antigenBiomarkersBiomarkers in medicine
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute hea…

2017

Aim: Baseline values of N-terminal pro B-type natriuretic peptide (NT-proBNP) and carbohydrate antigen 125 (CA125) predict all-cause mortality in acute heart failure (AHF). However, there is limited information about the added prognostic benefit of using longitudinal values, and how this predictive ability is modified when modelling together. The aim of this study was to determine the mutually-adjusted association between the longitudinal trajectories of NT-proBNP and CA125 with all-cause mortality after an episode of AHF. Methods and results: We included 946 consecutive patients discharged for AHF. NT-proBNP and CA125 were measured at each physician-patient encounter (median (interquartile…

Malemedicine.medical_specialtyLongitudinal studyTime Factorsacute heart failuremedicine.drug_class030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineRisk Assessment03 medical and health sciences0302 clinical medicineInterquartile rangeRisk FactorsInternal medicineCause of DeathNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineMortalitycarbohydrate antigen 125Survival rateCause of deathAgedRetrospective StudiesHeart Failurebusiness.industrylongitudinal studyMembrane ProteinsRetrospective cohort studyGeneral MedicineBrain natriuretic peptidemedicine.diseasePrognosisPeptide FragmentsSurvival RateEndocrinologyB-type natriuretic peptideSpainHeart failureCA-125 AntigenAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesEuropean heart journal. Acute cardiovascular care
researchProduct

Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation

2019

Galectin-3 (Gal-3) and carbohydrate antigen 125 (CA125) have been associated with adverse outcomes after transcatheter aortic valve implantation (TAVI). Experimental data have suggested a potential molecular interaction. Therefore, we assessed the association of Gal-3 and CA125 with prognosis after TAVI.A total of 439 patients were enrolled. The primary endpoint was a composite of all-cause mortality or readmission for worsening heart failure after TAVI.The primary endpoint occurred in 16.4%. Gal-3 was dichotomized at ≥ 8.71 ng/mL into elevated and not elevated. Gal-3 was elevated in 31.9% and was associated with a higher risk of the primary endpoint (25% vs 12.4%, HR, 2.26; P.001). After m…

Malemedicine.medical_specialtyTranscatheter aorticAdverse outcomesGalectin 3030204 cardiovascular system & hematologyRisk AssessmentTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineRisk FactorsCause of DeathGermanyInternal medicinemedicineClinical endpointHumansIn patientAgedRetrospective StudiesAged 80 and overbusiness.industryAortic Valve StenosisGeneral MedicinePrognosismedicine.diseaseSurvival RateGalectin-3CA-125 AntigenHeart failureAortic valve stenosisCardiologyFemalebusinessCarbohydrate antigenBiomarkersFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct

Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation

2017

Elevated carbohydrate antigen 125 (CA125) and N-terminal pro-brain natriuretic peptide (NTproBNP) have been associated with adverse outcome after transcatheter aortic valve implantation (TAVI). This study performs a comparison of both biomarkers for prognosis after TAVI. The study includes 363 patients. The primary end point was all-cause death or readmission for worsening congestive heart failure within 1 year after TAVI, and this end point occurred in 16% of the population. The optimal cutoff to predict the primary end point was 18.4 U/ml for CA125 and 2,570 ng/L for NTproBNP. Elevated CA125 levels were present in 52% and were associated with a higher rate of the primary end point (27% vs…

Malemedicine.medical_specialtyTranscatheter aorticmedicine.drug_classPopulation030204 cardiovascular system & hematologyRisk AssessmentTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicinePredictive Value of TestsGermanyInternal medicineNatriuretic Peptide BrainNatriuretic peptideClinical endpointHumansMedicine030212 general & internal medicineeducationAged 80 and overHeart Failureeducation.field_of_studybusiness.industryAortic Valve StenosisPrognosismedicine.diseasePeptide FragmentsCA-125 AntigenPredictive value of testsHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessCarbohydrate antigenBiomarkersN-terminal pro-Brain Natriuretic PeptideThe American Journal of Cardiology
researchProduct

Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization …

2012

Recent observations in chronic stable heart failure suggest that high-dose loop diuretics (HDLDs) have detrimental prognostic effects in patients with high blood urea nitrogen (BUN), but recent findings have also indicated that diure- tics may improve renal function. Carbohydrate antigen 125 (CA125) has been shown to be a surrogate of systemic congestion. We sought to explore whether BUN and CA125 modulate the mortality risk associated with HDLDs following a hospitalization for acute heart failure (AHF). Methods and results We analysed 1389 consecutive patients discharged for AHF. CA125 and BUN were measured at a mean of 72+12 h after admission. HDLDs (≥120 mg/day in furosemide equivalent d…

Malemedicine.medical_specialtymedicine.drug_classRenal functionGastroenterologyRisk AssessmentLoop diureticsBlood Urea NitrogenCohort StudiesSodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinemedicineHumansProspective StudiesMortalityProspective cohort studyBlood urea nitrogenAgedAged 80 and overHeart Failurebusiness.industryHazard ratioFurosemideAcute heart failureLoop diureticMiddle Agedmedicine.diseaseConfidence intervalfemale genital diseases and pregnancy complicationsHospitalizationBlood urea nitrogenEndocrinologyCarbohydrate antigen 125Heart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesEuropean journal of heart failure
researchProduct

Synthetic Glycopeptides of the Tandem Repeat Sequence of the Epithelial Mucin MUC4 with Tumour-associated Carbohydrate Antigens

2004

Glycohexadecapeptides representing the tandem repeat sequence of the epithelial mucin MUC4 were prepared by applying a solid-phase methodology. The required glycosyl amino acid building blocks containing the tumour-associated saccharide antigens T N -, T,- sialyl-T N , (2,6)- and (2,3)-sialyl-T were synthesized according to a straightforward biomimetic strategy by stepwise extension of the saccharide side chain of a Fmoc-protected galactosamine threonine tert-butyl ester.

chemistry.chemical_classificationTumor-Associated Carbohydrate AntigensChemistryOrganic ChemistryMucinGeneral MedicineMolecular biologyGlycopeptideAmino acidcarbohydrates (lipids)chemistry.chemical_compoundAntigenBiochemistryGalactosamineTandem Repeat SequenceSide chainGlycosylThreonineSynlett
researchProduct

Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

2020

Aims: \ud This retrospective analysis sought to identify markers that might distinguish between acute heart failure (HF) and worsening HF in chronic outpatients.\ud \ud Methods and Results: \ud The BIOSTAT‐CHF index cohort included 2516 patients with new or worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients (worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 outpatients. Multivariable models were developed in the index cohort using clinical characteristics, routine laboratory values, and proteomics data to examine which factors predict adverse outcomes in both conditions and to determine which factors differ between ac…

medicine.medical_specialtyAdverse outcomesacute heart failure treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemacute heart failure diagnosisInternal medicineOutpatientsDiagnosismedicineRetrospective analysisHumansAcute heart failure; acute heart failure diagnosis; acute heart failure treatmentRetrospective StudiesHeart Failurebusiness.industryTreatment developmentRoutine laboratoryAcute heart failurePrognosismedicine.diseaseR1[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHospitalizationTreatmentHeart failureChronic DiseaseCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessCarbohydrate antigen
researchProduct